Is TRXF11 Worth It in 2026? Full Analysis and Verdict

Is TRXF11 good? Straight verdict

Yes, TRXF11 is considered one of the best brick-and-mortar REITs in Brazil. The Rico aos Poucos analysis assigned a rating of 8.5 out of 10 and a BUY verdict. The fund ranks second among the ten peers analyzed in the high-quality brick-and-mortar-with-logistics segment, alongside BTLG11, BRCO11 and HSLG11.

The central argument is simple: TRXF11 delivers a rare combination of predictability and quality — 124 properties spread across 17 states, with 73.4% of revenue in long-term atypical contracts (WAULT of 13.2 years) and physical vacancy of just 0.67%. With the unit trading at P/BV of 0.93 — that is, 6.6% below book value — and a DY of 12.16%, the risk-reward relationship looks favorable for the investor with a medium-to-long-term horizon.

That said, the buy verdict does not mean an absence of risks. There are real points of attention that any investor should understand before taking a position — and that are explained in depth throughout this analysis.

Who TRXF11 is for — and who it is not

TRXF11 was built to generate stable monthly income protected by IPCA, not for aggressive dividend growth. Before buying, it is worth asking whether this profile makes sense for you:

Who it makes sense to invest in TRXF11

  • Investor focused on predictable monthly income, a retiree or in the pre-retirement phase who needs reliable income every month without worrying about DPS volatility.
  • Those who want a portfolio core of brick-and-mortar REITs of institutional quality — the fund can make up 5% to 15% of a REIT portfolio without excessive concentration.
  • Investor who values an inflation hedge: with 78% of revenue indexed to IPCA, income rises automatically with inflation at each rent revision.
  • Those who need high liquidity: with an average volume of R$ 22.9 million per day, TRXF11 is among the five most liquid REITs in the market — a R$ 1 million position can be sold in less than one trading session without impacting the price.

Who TRXF11 is not the right vehicle for

  • Those seeking aggressive DPS growth: atypical contracts cap the adjustment ceiling at IPCA. There are no positive surprises beyond inflation.
  • A pure Selic-drop speculator who wants high beta: REITs like GARE11 and BLMG11 have a larger discount to book value (P/BV close to 0.69-0.80) and more explosive appreciation potential if Selic falls to 11%.
  • Investor who already has more than 5% of the portfolio in HGRU11: the thesis overlap is high (same segments, same contract types, similar indexer). Holding both at a high weight does not diversify.
  • Those who need to avoid any exposure to retail under reorganization: the fund has 7.8% of revenue tied to PCAR3 (Pão de Açúcar) in out-of-court reorganization and a small property with Americanas in judicial reorganization (estimated weight below 0.8%). If that exposure, however small, bothers you, TRXF11 is not the right fund.

What are TRXF11's real risks?

There is a frequent confusion in TRXF11 analyses: the Management Report aggregates under the "Pão de Açúcar (GPA)" line a historical block of 24.24% of revenue. That number included, before 2021, contracts with the entire group. After the spin-off of Assaí (ASAI3) from GPA, the reality changed:

  • 7.8% of revenue is in fact with PCAR3 — the entity in out-of-court reorganization since March 2026, negotiating R$ 4.568 billion in financial debt with banks (BTG Pactual, HSBC, Itaú, Rabobank). In May 2026, the agreement obtained adhesion from 57.49% of creditors — above the legal minimum of 50%. Rents continue to be paid on time, because the out-of-court reorganization only affects financial debt, not operational obligations.
  • 16.4% of revenue is with Assaí (ASAI3) — a spun-off company, financially independent, with investment grade and outside any reorganization process. Treating this block as GPA risk is a reading error.

Other relevant points of attention:

  • New offering round signaled: The Material Fact of June 2, 2026 on the acquisition of 8 warehouses provides for partial payment via credits from a future unit offering. If realized at a P/BV below 1.0, there is a risk of value-per-unit dilution.
  • Execution of the hospital construction: Hospital Albert Einstein Parque Global (96% complete, delivery expected for July 2026) and Medical Center Parque Global (68% complete, delivery in September 2026) do not yet generate revenue. Delays postpone projected revenue, but the seller's contribution neutralizes the grace period.
  • Leverage: The fund has R$ 2.04 billion in CRIs, with an average cost of IPCA+6.55% (63.57% of the debt) and CDI+2.15% (36.43%). Net leverage of 9.11% is controlled, but the IPCA-indexed cost can rise if inflation gets out of control — mitigated by the match with revenue also indexed to IPCA.
  • Acquisition of the Hotel Emiliano: In May 2026, TRXF11 announced the purchase of the Hotel Emiliano property in Copacabana for about R$ 220 million, with an atypical contract through 2054. It is the first exposure to the hotel segment — more cyclical than food retail, although the atypical contract insulates the fund from the hotel's operations.

What is TRXF11's fair value?

The fair value calculated by the Rico aos Poucos methodology is R$ 99.17/unit, with a range of R$ 92.23 to R$ 106.11. With the unit trading around R$ 91.37, the discount to the estimated fair value is about 8% — a modest margin of safety for an institutional-quality fund.

Three methodologies make up the calculation:

  • Target DY over Selic+premium (40% weight): With a sustainable annual DPS of R$ 12.66 (base of R$ 0.93 × 12 plus the historical average of extras) divided by Selic of 14.75% plus an urban-income premium of 4.5%, the implied price would be R$ 65.77. This component pulls fair value down — a direct reflection of the high Selic.
  • P/BV from peers (30% weight): The current NAV/unit is R$ 99.98. Applying the segment peer median P/BV (0.97), the implied price is R$ 96.98. TRXF11 deserves to trade close to the median given the portfolio's quality.
  • DY from peers (30% weight): With an annual DPS of R$ 12.66 divided by the peer median DY (11.84%), the implied price is R$ 106.93 — a reflection that TRXF11 delivers a yield above the median with a higher-quality portfolio.

The fair value of R$ 99.17 takes into account a quality factor of 0.945, which positively weighs the manager TRX (top 3 in the segment), the 0.46% vacancy, the 12-year WAULT and DPS stability. Selic at 14.75% is the main factor keeping fair value depressed relative to book value. If Selic falls to 11% (the Focus 12-month projection), fair value should rise to R$ 105 or more — generating appreciation potential on top of the current DY.

Is it worth buying TRXF11 today? Analysis conclusion

TRXF11 deserves the 8.5 rating and the buy verdict for a combination that few funds manage to assemble: scale, real diversification, a top-tier manager and contracts that protect the unitholder for an entire decade. In June 2026, the unit was 6.6% below book value (P/BV 0.93), the embedded DY was about 12.16% and the manager reiterated guidance of R$ 0.90 to R$ 0.93 through December 2026.

The short-term catalysts are concrete: the sale of 9 properties was completed in June 2026, with an extraordinary distribution expected between R$ 1.30 and R$ 1.80/unit; the delivery of Hospital Albert Einstein is scheduled for July; and the Selic-easing cycle projected for the next 12-24 months tends to compress the DY-Selic spread and reprice brick-and-mortar REITs upward.

For the long-term investor focused on income, TRXF11 works as a REIT portfolio core that combines inflation protection, monthly cash-flow predictability and exceptional liquidity. It is not the cheapest fund nor the one that will deliver the greatest DPS growth — but it is probably the most reliable in the urban-income segment. Those seeking just one brick-and-mortar REIT to anchor the portfolio find here one of the best options available on B3. Information on monthly dividends and the live price of TRXF11 is available in dedicated sections of this platform.

Frequently asked questions

Is TRXF11 good or bad?

TRXF11 is considered a good brick-and-mortar REIT. It received a 8.5 rating and a BUY verdict in the Rico aos Poucos analysis, for combining 124 properties, a WAULT of 13.2 years, vacancy of 0.67% and a DY of 12.16%. It is suitable for those seeking predictable monthly income with inflation protection.

Is TRXF11 worth it in 2026?

Yes, for the income profile. In 2026, the fund has a P/BV of 0.93 (6.6% below book value), a DY of 12.16% and confirmed guidance of R$ 0.90 to R$ 0.93/unit through December. Near-term catalysts include completion of the sale of 9 properties and the delivery of two hospitals.

What is TRXF11's fair value?

The calculated fair value is R$ 99.17/unit (range of R$ 92.23 to R$ 106.11). With the unit around R$ 91.37, the discount is about 8%. In a scenario of Selic falling to 11%, fair value should rise to R$ 105 or more.

What are TRXF11's risks?

The main risk is the 7.8% revenue exposure to PCAR3 (Pão de Açúcar) in out-of-court reorganization — not 24%, since the other 16.4% of the GPA block is Assaí, an independent company with investment grade. Other risks: a possible new unit offering with dilution and execution of the hospital construction.

TRXF11 buy or sell?

Buy, according to the Rico aos Poucos analysis (8.5 rating). It makes sense for an income investor with a medium-to-long-term horizon. It is not suitable for those seeking aggressive DPS growth or who want to avoid any exposure to retail under debt renegotiation.

TRXF11 or GARE11 — which is better?

It depends on the goal. GARE11 is more discounted (lower P/BV) with greater appreciation potential if Selic falls, but has a smaller portfolio. TRXF11 is larger, more diversified (124 properties vs GARE11's smaller portfolio) and with a superior WAULT. For a portfolio core, TRXF11; for a discount trade, GARE11.

Related searches about the TRXF11 analysis

  • is trxf11 good
  • trxf11 expert analysis
  • trxf11 good or bad
  • is trxf11 worth it
  • trxf11 still worth it
  • trxf11 analysis
  • trxf11 buy or sell
  • trxf11 fair value